EXHIBIT B TO DECLARATION OF WENDY L. DEVINE IN SUPPORT OF BENCH BRIEF RE NEXUS AND XLIF



Case 3:18-cv-00347-CAB-MDD Document 390-3 Filed 03/04/22 PageID.34750 Page 2 of 5

```
1
                       UNITED STATES DISTRICT COURT
 2
                     SOUTHERN DISTRICT OF CALIFORNIA
 3
         BEFORE HONORABLE CATHY ANN BENCIVENGO, JUDGE PRESIDING
 4
 5
     NUVASIVE, INC., a Delaware
     Corporation,
 6
                                         CASE NO. 18CV0347-CAB-MDD
                        Plaintiff,
 7
                                         SAN DIEGO, CALIFORNIA
              VS.
 8
                                         WEDNESDAY MARCH 2, 2022
     ALPHATEC HOLDINGS, INC., a
 9
     Delaware Corporation, and
     ALPHATEC SPINE, INC., a
10
     California corporation,
11
                        Defendants.
12
13
14
15
        STENOGRAPHIC COURT REPORTER'S TRANSCRIPT OF PROCEEDINGS
16
                       JURY TRIAL DAY 2, VOLUME 2
17
                               PAGES 1-223
18
19
20
21
22
     Proceedings reported by stenography, transcript produced by CAT
23
24
                   Mauralee Ramirez, RPR, CSR No. 11674
               Federal Official Stenographic Court Reporter
25
                        ordertranscript@gmail.com
```



success that aren't attributable directly to the instruments at issue in the case. I understand it's a system, but you can't use the whole system and praise for the whole system to defeat an argument that the various components that are at issue here are -- weren't obvious in the industry. They still have to prove all that. But that's my concern, and I'm not necessarily expecting an answer from counsel today. I'm just kind of putting it out there as a concern that I have.

ATTORNEY DEVINE: So, Your Honor, the claims do cover neuromonitoring and able dilators. The neuromonitoring itself — and there's been a lot said about this, so I'll give you my perspective on it and what I think we're going to hear from Dr. Youssef. The neuromonitoring itself is not the entirety of the invention. The retractor itself is designed to move in a very specific way. It's very specific for the psoas muscle to minimize retraction time and minimize the amount of retraction which is integral to avoiding damage to the nerves even from pressure. So the retractor itself is innovative. I know counsel will disagree with me. My perspective is they have not identified that unique nature of that retractor in the prior art. That was the invention and the invention of putting that together with dilators that can neuromonitor is the inventive system.

Now as far as nexus and secondary considerations, we can brief this. This has not come up previously in the case,



Case 3:18-cv-00347-CAB-MDD Document 390-3 Filed 03/04/22 PageID.34752 Page 9 of 5

so we would have briefed it on a motion. But the law states that there's a presumption if the embodiment reads on the claims. However, even if you can't meet that presumption, you can still show that the elements of the claims are leading to the secondary considerations. It doesn't have to be every single thing that is leading to the secondary considerations is in the claim. In fact, the Federal Circuit said if that was the standard, that would be near impossible because there's always something, right? Even your refrigerator, you have to plug it into the wall. It's not going to cool anything off without electricity. And this is sort of, although on a very high level, analogous to that, right? We have a dilator that a neuromonitor can work integrally with a retractor that is specially designed and functions in a very particular way that is claimed. All these limitations are claimed. And that dilator, yes, has to be plugged into a system that is going to allow that electrode to sense the nerves, but that doesn't mean that the system itself is not what is the subject of the praise.

THE COURT: Go ahead.

ATTORNEY WICKRAMASEKERA: Your Honor, that's not -first off, that's not a correct statement of the law. The law
is not that there's not a nexus just because the claims cover
the product. They have to be coextensive, and according to the
Federal Circuit that means the claim is the product.



1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

If Your Honor would like a bench brief on this issue, we're happy to provide one, but the Federal Circuit itself has stated that XLIF requires NeuroVision. That's in a Federal Circuit opinion. We would be happy to provide that.

THE COURT: Again, I don't want to hold us up today on this. I would like something in writing with some case support. I do think that there is an issue here that because of the problem that there's been testimony to the problem with the side entry, this lateral entry system of doing it. One of the big hurdles that had to be overcome was all of the nerves in this muscle. And just because you have a dilator that's got little neuromonitors on it, if it's not plugged into something, who cares? It's not going to detect anything. So the monitoring part, which is fully in your specification as part of this patent which all these claims flow from, I don't think you get to distinguish out that aspect of it in terms of the acceptance historically of the system that the system was more than just the tools, but rather also involved the tools plugged in. And that's not one of the claims here.

So, again, there may be other claims in this patent, where that's not a problem but for these for secondary considerations of non-obviousness for these claims, there may be not be enough there. I'm not ruling, just saying so. And I don't want to hear more argument on it today. I would like you to brief it. And if I can have those briefs for Friday, I can



2.1